Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
The coronavirus might not pose the threat it once was, and Novavax (NASDAQ: NVAX) can be considered a laggard in the Great COVID-19 Vaccine Race, but the stock certainly has plenty of believers. The more important of these two filings was with the U.S. Food and Drug Administration (FDA). Novavax's money product of the moment, its coronavirus vaccine Nuvaxovid, won emergency use authorization (EUA) from the American regulator last month.